Metronomic vinorelbine shows benefit in metastatic NSCLC

  • Pujol JL & al.
  • PLoS One
  • 1 Jan 2019

  • curated by Craig Hicks
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Metronomic oral vinorelbine (MOV) is an active and well-tolerated chemotherapy for metastatic NSCLC.

Why this matters

  • Previous studies evaluating MOV for treating metastatic NSCLC were limited by small sample sizes.

Study design

  • Patient-level meta-analysis of 9 studies involving 418 patients (mean age, 72.8±9.1 years; 79.2% male) receiving oral vinorelbine 30-50 mg thrice weekly.
  • Most (82.1%) had a stage IV disease; 80% had 1-4 frailty characteristics.
  • Funding: Pierre Fabre Oncology.

Key results

  • Median OS was 8.7 (95% CI, 7.6-9.5) months.
  • OS after starting vinorelbine was 64% at 6 months, 30.3% at 1 year, and 8.9% at 2 years.
  • Median PFS was 4.2 (95% CI, 3.9-5) months.
  • PFS was 35% at 6 months and 11.9% at 1 year.
  • No toxicity was reported in 40% of patients; 15.8% experienced grade 3-4 toxicity.

Limitations

  • Studies included in the analysis had small sample sizes and different follow-up schedules.